Drug Profile
Petosemtamab - Merus
Alternative Names: EGFR x LGR5 Biclonics®; Lgr5 x EGFR Biclonics®; MCLA 158Latest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Merus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 07 Aug 2023 Merus plans a phase III trial for head & neck squamous cell carcinoma (Monotherapy, Second-line therapy or greater) in 2024
- 04 Aug 2023 Petosemtamab - Merus receives Fast Track designation for Squamous cell cancer [IV] (Second-line therapy or greater, Recurrent, Metastatic disease) in USA
- 23 Jun 2023 Phase-I/II clinical trials in Squamous cell cancer (Second-line therapy or greater) in United Kingdom, United Kingdom, Spain, France, Belgium (IV) (NCT03526835)